Premium
Synthesis, Biological Evaluation and Molecular Modeling Studies of New 2,3‐Diheteroaryl Thiazolidin‐4‐Ones as NNRTI s
Author(s) -
Debnath Utsab,
Verma Saroj,
Singh Pankaj,
Rawat Kavita,
Gupta Satish K.,
Tripathi Raj K.,
Siddiqui Hefazat H.,
Katti Seturam B.,
Prabhakar Yenamandra S.
Publication year - 2015
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12591
Subject(s) - nevirapine , reverse transcriptase , chemistry , docking (animal) , substituent , stereochemistry , human immunodeficiency virus (hiv) , molecular model , molecular dynamics , nucleoside reverse transcriptase inhibitor , nucleoside , combinatorial chemistry , computational biology , biochemistry , biology , virology , computational chemistry , rna , medicine , gene , antiretroviral therapy , nursing , viral load
In a focused exploration, thiazolidin‐4‐ones with different C ‐2 and N ‐3 substituent groups were synthesized and evaluated as non‐nucleoside reverse transcriptase inhibitors against HIV ‐1. This has led to new active compounds sporting heteroaryls at both C ‐2 and N ‐3 positions prompting to view them in the backdrop of nevirapine. To assign the molecular attributes for the activity, the compounds are investigated by docking them into non‐nucleoside inhibitor‐binding pocket of HIV ‐1 reverse transcriptase ( RT ). The most active compounds of this series ( 7d and 7f ) shared spatial features with nevirapine with added molecular flexibility. Furthermore, in molecular dynamics simulations carried out for up to 10 ns, the compounds 7d and 7f showed consistency in their interactions with non‐nucleoside inhibitor‐binding pocket of HIV ‐1 RT and suggested T yr319 and V al106 as potential residues for H ‐bond interaction with these molecules. These results open new avenues for the exploration of 2,3‐diheteroaryl thiazolidin‐4‐ones for prevention of HIV ‐1.